The safe/right choice is H. Zoster. You never fully eradicate invasive fungal or NTM infections. HBV is too risky to again use TNFi again. After H.zoster is Rx,there is evidence its safe to restart TNFi without risk of recurrence. Vagal N. Stim is the mechanistically same as

Retrospective Intl SSc study of MD & PT telangiectasia counts (TC) (0, 1–6, 7–15 or > 15) of face, forearms & hands. High TC correlated w/ PAH (AUC 0.824–0.875) & digital ulcers. Moderate agreement betw MD & Pt for face & forearms TC (kappa 0.648 & 0.605, p< 0.001) https://t.co/jtHgVABFiA

Case-control study of 349 autoimmune (ARD) pts (SLE, RA, SSc) & serum assays for anti-neutrophil extracellular trap (aNET)Abs. aNET in 37% SLE assoc w/ APS (OR 3.4) & arterial thrombosis (OR 5.5). aNET in 40% RA assoc w/ ACPA+ (p=0.049) https://t.co/QwvmLAVmg7 https://t.co/VJ7JV5fcZE

• Anti-neutrophil extracellular trap antibodies in autoimmune rheumatic diseases:…

Best JAKi? Italian Observational BIRRA Cohort study of 170 #PsA pts Rx w/ UPA or TOFA found no significance in 6 mos (86 vs 78%) or 12 mos (68 v 60%) retention. Persistence lower in pts Concomitant or later csDMARDs. https://t.co/vtSrO9orh4

• Frontiers | Comparative Effectiveness of Upadacitinib vs Tofacitinib in Psoriat…

Canada’s Drug Agency (CDA-AMC) has recommended Gazyva (obinutuzumab) for public reimbursement. This recommendation is for the treatment of adult patients with active lupus nephritis who are receiving standard therapy https://t.co/TC1MVAShdC https://t.co/flXVmLwGtW

• Gazyva® (obinutuzumab) receives positive reimbursement recommendation from Cana…

"Courage is resistance to fear, mastery of fear, not absence of fear." - Mark Twain https://t.co/xyJqiV7biI

RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?

Plasmacytoid dendritic cells (pDCs) have been strongly implicated in the pathogenesis of lupus, as their primary product, type I interferon (IFN-I), drive systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). A recent comprehensive review synthesizes the https://t.co/VaE295a2Ep

Let me give you an example of where there is no gov intervention, and the impact on brand drug pricing. When a brand manufacturer sells a drug to one of the big 3 drug distributors that control more than 90 pct of their market, those multi hundred billion dollar distributors

A Practical Approach to Myositis-Specific Antibodies https://t.co/14qow6zhsD

• https://x.com/aabdogafar/status/2058474657192292627/photo/1

True or False: In a Japanese study of refractory neuropsychiatric SLE, rituximab led to significant improvement in the majority of patients treated. See if you got it right at https://t.co/3F1h89Qrtw https://t.co/vx0ILsZ3WF

• RheumIQ Weekly Quiz | RheumNow

NLRP3 inflammasome activation triggers PAD (2, 4) release from human neutrophils, increasing citrullination of intracellular proteins (CCPs) and driving the pathogenesis of #RA. Further proof: , PAD concentrations and PAD activity correlate with IL-1β.https://t.co/pRQy0ECG5d https://t.co/HExIhebJ4u

• NLRP3 inflammasome promotes PAD2/PAD4 release and protein citrullination in rhe…

RHEUM Survey: After treating which infection can you safely resume anti-TNF therapy?